Richard A. Gonzalez - Feb 16, 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: CHAIRMAN OF THE BOARD AND CEO, Director
Signature: Steven L. Scrogham, attorney-in-fact for Richard A. Gonzalez
Stock symbol: ABBV
Transactions as of: Feb 16, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/21/2023, 05:06 PM
Previous filing: Mar 1, 2022
Next filing: Mar 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+150K	+29.75%	$0.00	653K	Feb 16, 2023	Direct	F1
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+34.9K	+5.35%	$0.00	688K	Feb 16, 2023	Direct	F2
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+39K	+5.67%	$0.00	727K	Feb 16, 2023	Direct	F3
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+33.2K	+4.57%	$0.00	760K	Feb 16, 2023	Direct	F4
holding	ABBV	Common Stock, $0.01 par value						17.6K	Feb 16, 2023	By Spouse	F5
holding	ABBV	Common Stock, $0.01 par value						5.9K	Feb 16, 2023	By Step-daughter	F5
holding	ABBV	Common Stock, $0.01 par value						5.9K	Feb 16, 2023	By Step-son	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABBV	Option (Right to Buy)	Award	$0	+115K		$0.00	115K	Feb 16, 2023	Common Stock	115K	$149.62	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F2	Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F3	Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F4	Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F5	The reporting person disclaims beneficial ownership of these securities.
F6	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,263 on February 16, 2024, 38,262 on February 16, 2025, and 38,262 on February 16, 2026.